FDA Committee to Review Nuplazid in Treating Alzheimer’s Psychosis

Home / Alzheimer's / FDA Committee to Review Nuplazid in Treating Alzheimer’s Psychosis
FDA Committee to Review Nuplazid in Treating Alzheimer’s Psychosis
May 10, 2022May 10, 2022
0

A U.S. Food and Drug Administration (FDA) advisory committee will host a virtual meeting to review a request to expand the approval of Nuplazid (pimavanserin) to include psychosis due to Alzheimer’s disease dementia. The FDA’s Psychopharmacologic Drugs Advisory committee meeting on the application recently submitted by Acadia Pharmaceuticals, which developed and markets Nuplazid, is scheduled for June 17. The committee’s decision is expected by Aug. 4. “We appreciate our ongoing engagement with the FDA and look forward to a productive discussion…

You must be logged in to read/download the full post.